Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
Conclusions: Patients with non-severe pneumonia at admission and whose fever resolved within two days of treatment are more likely to improve with favipiravir.
Source: The Journal of Infection in Developing Countries - Category: Infectious Diseases Source Type: research
More News: COVID-19 | Cytokine Therapy | Infectious Diseases | Intensive Care | Laboratory Medicine | Pneumonia | Radiography | Respiratory Medicine | Study